Sees FY25 revenue $729M-$737M, consensus $727.5M
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen reports Q3 adjusted EPS 46c, consensus 42c
- Is RGEN a Buy, Before Earnings?
- Novo Nordisk update raises questions on Repligen approval, says Canaccord
- Repligen price target raised to $160 from $150 at Barclays
- Repligen’s Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning